These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087 [TBL] [Abstract][Full Text] [Related]
11. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460 [TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415 [TBL] [Abstract][Full Text] [Related]
13. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM; Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981 [TBL] [Abstract][Full Text] [Related]
14. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution. Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Vallespí T; Imbert M; Mecucci C; Preudhomme C; Fenaux P Haematologica; 1998 Mar; 83(3):258-75. PubMed ID: 9573680 [TBL] [Abstract][Full Text] [Related]
16. Prognostic scoring systems in MDS. Germing U; Kündgen A Leuk Res; 2012 Dec; 36(12):1463-9. PubMed ID: 22980036 [TBL] [Abstract][Full Text] [Related]
17. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G; J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153 [TBL] [Abstract][Full Text] [Related]
18. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029 [TBL] [Abstract][Full Text] [Related]
20. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]